Last update 08 Sep 2025

Epcoritamab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Anti-CD3 anti-CD20 bispecific antibody, Anti-CD3 anti-CD20 bispecific antibody(Genmab A/S), epcoritamab-bysp
+ [7]
Action
inhibitors, stimulants
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Australia), Conditional marketing approval (European Union)
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Large B-cell lymphoma
Canada
13 Oct 2023
Recurrent Grade 3b Follicular Lymphoma
Canada
13 Oct 2023
Mediastinal large B-cell lymphoma
Japan
25 Sep 2023
Recurrent Follicular Lymphoma
Japan
25 Sep 2023
Refractory Follicular Lymphoma
Japan
25 Sep 2023
Diffuse large B-cell lymphoma recurrent
European Union
22 Sep 2023
Diffuse large B-cell lymphoma recurrent
Iceland
22 Sep 2023
Diffuse large B-cell lymphoma recurrent
Liechtenstein
22 Sep 2023
Diffuse large B-cell lymphoma recurrent
Norway
22 Sep 2023
Diffuse large B-cell lymphoma refractory
European Union
22 Sep 2023
Diffuse large B-cell lymphoma refractory
Iceland
22 Sep 2023
Diffuse large B-cell lymphoma refractory
Liechtenstein
22 Sep 2023
Diffuse large B-cell lymphoma refractory
Norway
22 Sep 2023
Diffuse Large B-Cell Lymphoma
United States
19 May 2023
High grade B-cell lymphoma
United States
19 May 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Grade 3a Follicular LymphomaPhase 3
United States
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
China
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
Japan
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
Australia
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
Belgium
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
Bulgaria
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
Canada
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
Croatia
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
Czechia
05 Feb 2024
Refractory Grade 3a Follicular LymphomaPhase 3
Denmark
05 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
450
bymdcdudlw(jwjdumwzco) = statistically significant and clinically meaningful improvements in overall response rate (ORR) and progression-free survival (PFS) in patients with relapsed or refractory FL. gekoskvbua (lfqiumfuso )
Positive
08 Aug 2025
Phase 3
Follicular Lymphoma
Second line | Last line | Third line
CD20 positive
-
wcemvnhold(hhxlupkarb) = tqhzwcdich vmhgvfsppd (yuyzouadch )
Positive
07 Aug 2025
-
Phase 1/2
21
ulygclkmqm(rowaewqqxl) = mostly low grade rvtbphghgt (rwrcijhpib )
Positive
09 Jul 2025
Phase 1/2
42
kvatwihlcf(ntmpgoceyp) = pckbvghxsu eyvzevtjzq (ufcplqzgsv )
Positive
30 May 2025
Phase 1/2
Large B-cell lymphoma
Third line
CD20
157
gprjbbtdat(cuyxoqvjkz) = 12 D/C for reasons other than PD, most commonly adverse events (n=6, including the 2 pts with fatal infections above) rqjfaqcmeo (idlsamzgkh )
Positive
30 May 2025
Placebo
Phase 2
157
pzrlyvdbix(uqxveuyunt) = kwakcexjwe nsnexlojqf (szffwgmhxr )
Positive
22 May 2025
Phase 1/2
37
avbeqjgbqu(ivwgourqce) = fckaurjvmb dtqrrkelhm (jekfxkudjl )
Positive
14 May 2025
Not Applicable
-
26
CD3/CD20 Bispecific Antibodies
amhesbwzzn(bjsovxbcrp) = During a total exposure time of 158.1m, 37 infectious episodes were observed, representing an incidence of 0.23 patient-month. The median number of infections per patient was 1 episode, with 18 of 26 patients presenting at least one. Two infections were identified during the first month of treatment, 18 between 1-6m and 17 after 6 months of therapy. Regarding severity, 24 were G1-2, 11 G3-4 and 2 were G5 (Klebsiella and Pseudomonas bacteremias). Most common foci of infection were respiratory (45%), followed by bloodstream (24%), urinary (13%) and gastrointestinal (10%). An etiologic agent was identified in 27 episodes. Of those, half were viral infections, including SARS-CoV2 (8), Influenza A (2) and Cytomegalovirus reactivation (4); 40% were bacterial; one patient had invasive aspergillosis and one had intestinal giardiasis. iaxbidietd (ygjjifjije )
-
14 May 2025
Phase 1/2
Diffuse Large B-Cell Lymphoma
First line
CD3 | CD20
28
Epcoritamab + R-miniCHOP
jshgloirew(qoruftevxu) = mpefphcwfl dnehsmwdce (onznbjzaug )
Positive
14 May 2025
R-miniCHOP
jshgloirew(qoruftevxu) = zezrqhllov dnehsmwdce (onznbjzaug )
Phase 1/2
31
kmqighqhyf(izwutoguss) = 68% xvcriigbji (ajqhvwwser )
-
14 May 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free